28 June 2022 - The Federal Ministers give a final decision (positive with conditions) for this trial, without prejudice to other applicable legislation
Trial reference:
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors